BMY
Bristol-Myers SquibbDNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
Successful late-stage readouts or favorable regulatory outcomes plus stable core product sales drive multiple expansion toward the analyst high; acquisition or clearer long-term guidance could lift the stock to the bull target.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Clinical trial failure or delay
Momentum
32
Value
68
Sentiment
37
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $57.68 · Bull $68.00 · Bear $37.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-02-06 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $62.65
Why
Momentum32 · Δ7d +2.3
Value68 · Δ7d -0.1
Sentiment37 · Δ7d -8.2
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
32
26% active weight
Current posture
7d trendImproving
Δ7d
+2.3
Δ21d
-8.5
Value
68
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.2
Sentiment
37
34% active weight
Current posture
7d trendSoftening
Δ7d
-8.2
Δ21d
-6.7
Why this grade
Composite grade D. Momentum 32.1 / Value 68.4 / Sentiment 37.4
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$122.85B
Beta
0.29
Shares Out
2.04B
P/E (TTM)
17.9
P/S (TTM)
2.25
P/FCF (TTM)
10.49
Rev YoY
+2.6%
EPS YoY
+8.6%
Gross Margin
+66.1%
Op Margin
+20.0%
Net Debt
$36.47B
Current Ratio
1.42
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology